Results 251 to 260 of about 232,812 (303)

Clinical Profile of Venous Thromboembolism and Applicability of the ThroLy and IMPEDE VTE Risk Scores in Patients With Lymphoma and Multiple Myeloma: A Moroccan Single-Center Retrospective Study. [PDF]

Cureus
Mnafe O, Jamlaoui A, Eddou H.
europepmc   +1 more source

A solitary lytic rib lesion mimicking primary Chest Wall malignancy as the initial presentation of multiple myeloma. [PDF]

Oxf Med Case Reports
Tombul İ, Valiyev E, Akbal Ersöz TA, Zengin M.   +3 more
europepmc   +1 more source

Fulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report. [PDF]

Ther Adv Hematol
Wei Y, Yang X, Zheng Y, Zhang D.
europepmc   +1 more source

Complications of vertebral augmentation in metastatic spinal fractures: a systematic review of multiple study designs. [PDF]

J Bone Oncol
Correia MC, Vieira AM, Duarte F, Rodrigues Pinho A, Serdoura F, Leite MJ.   +5 more
europepmc   +1 more source

Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors. [PDF]

Blood Neoplasia
Tan W, Dai J, Kunacheewa C, Becnel MR, Lee HC, Patel KK, Berrios Nolasco DA, Huang M, Vora AU, Thomas SK, Pasvolsky O, Lutter-Berka Z, Kuiatse I, Korde NS, Jagannath S, Landgren O, Liu S, Manasanch EE, Orlowski RZ.   +18 more
europepmc   +1 more source

Multiple myeloma [PDF]

Nature Reviews Disease Primers, 2017
Multiple Myeloma (MM) is a cancer of plasma cells resulting from the abnormal proliferation of malignant plasma cells within the bone marrow (BM) microenvironment. MM accounts for 1.3% of all malignancies and 12% of hematologic cancers, and is the second
Shaji K Kumar, Pieter Sonneveld, S Vincent Rajkumar   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Plasma cell myeloma with D-myeloma protein (IgD myeloma)

The American Journal of Medicine, 1968
Abstract Plasma cell myeloma distinguished by a serum D-myeloma protein has been found in many parts of the world and more than two dozen cases have been identified. Noteworthy observations are the high frequency (80 per cent) of D-myeloma protein with lambda-light chains (D-myeloma protein—type L) and the almost invariable presence of Bence Jones ...
J L, Fahey, P P, Carbone, D S, Rowe, R, Bachmann   +3 more
openaire   +2 more sources

Multiple myeloma

The Lancet, 2021
Multiple myeloma is the second most common haematological malignancy in high-income countries, and typically starts as asymptomatic precursor conditions-either monoclonal gammopathy of undetermined significance or smouldering multiple myeloma-in which initiating genetic abnormalities, such as hyperdiploidy and translocations involving the ...
Niels W C J, van de Donk, Charlotte, Pawlyn, Kwee L, Yong   +2 more
openaire   +2 more sources

Myeloma

Disease-a-Month, 1990
Myeloma is a malignancy of plasma cells that are terminally differentiated B-lymphocytes. The clinical spectrum varies from the incidental discovery of a pathologically raised monoclonal immunoglobulin on routine electrophoresis in asymptomatic patients to widespread skeletal involvement with incapacitating bone pain.
openaire   +2 more sources

Multiple myeloma

Nursing Standard, 2014
Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes.
Gautam Raju, Mehta, Faten, Suhail, Rami Y, Haddad, Ghassan, Zalzaleh, Edgar V, Lerma   +4 more
  +7 more sources